Detalhe da pesquisa
1.
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
Hematol Oncol
; 41(3): 578-582, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36043430
2.
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.
Br J Haematol
; 192(3): 568-576, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33341940
3.
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
Br J Haematol
; 188(2): 283-294, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31423579
4.
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Haematologica
; 102(4): 785-795, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28034989
5.
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
Br J Haematol
; 158(6): 727-38, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22804669
6.
Protease Activity Analysis: A Toolkit for Analyzing Enzyme Activity Data.
ACS Omega
; 7(28): 24292-24301, 2022 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35874224
7.
Aging and matrix viscoelasticity affect multiscale tendon properties and tendon derived cell behavior.
Acta Biomater
; 143: 63-71, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35278685
8.
Multiscale profiling of protease activity in cancer.
Nat Commun
; 13(1): 5745, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36192379
9.
Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis.
Blood
; 113(9): 1992-2002, 2009 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-19060246
10.
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
Leuk Res
; 81: 62-66, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31035033
11.
The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker.
Expert Rev Mol Diagn
; 18(4): 319-329, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29504446
12.
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
Target Oncol
; 13(1): 39-47, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29230672
13.
Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).
Leuk Res
; 57: 45-54, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28288323
14.
Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects.
Mol Cancer Res
; 15(5): 598-609, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28122920
15.
Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Clin Cancer Res
; 22(13): 3383-97, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26960399
16.
A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay.
Int J Oncol
; 37(1): 71-9, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20514398
17.
Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth.
Blood
; 110(1): 287-95, 2007 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17369488